zenith20-4: efficacy & safety of poziotinib in treatment-naïve nsclc with her2 exon 20 mutations
Published 3 years ago • 180 plays • Length 4:24Download video MP4
Download video MP3
Similar videos
-
3:49
zenith20: poziotinib in egfr and her2 exon 20 mutant nsclc
-
1:58
zenith20: poziotinib efficacy and safety in nsclc
-
2:51
zenith20-5: poziotinib for egfr/her2 exon 20 mutant nsclc
-
1:32
poziotinib in treatment-naïve nsclc with her2 exon 20 mutations
-
3:39
poziotinib in pretreated patients with her2 exon 20 insertion nsclc
-
3:53
poziotinib in pretretaed, her2 exon 20 insertion nsclc
-
7:47
dr ashish bakshi, efficacy of poziotinib in her2 exon 20 insertion nsclc | crsf
-
5:54
dr shruti kate | poziotinib for patients with her2 exon 20 mutant non small cell lung cancer results
-
3:58
current treatments and challenges for patients with egfr exon 20 insertion-positive nsclc
-
28:19
clinical trial shows potential of poziotinib for her2-mutant lung cancer | celltalk
-
5:27
poziotinib data in egfr exon 20-mutant nsclc
-
0:53
treatments for patients with nsclc carrying egfr exon 20 insertions
-
5:49
targeting her2 mutations in nsclc: what do we know?
-
1:32
real-world comparison assesses mobocertinib in nsclc with egfr exon 20
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
6:57
egfr exon 20 mutations in non–small cell lung cancer
-
1:42
mobocertinib for previously treated nsclc with efgr mutations
-
1:29
poziotinib for her2-positive metastatic breast cancer